clinical trial · NCT01679002
Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers
Bial - Portela C S.A.·phase1·completed·n = 12
EpilepsyBIA 2-093Oxcarbazepine
brief summary
To investigate the steady-state pharmacokinetics of once-daily and twice-daily regimens of BIA 2-093 and twice-daily regimen of Oxcarbazepine (Trileptal®) in healthy subjects and to assess the tolerability of such regimens in healthy subjects.
started
Oct 1, 2003
primary completion
Dec 1, 2003
completion
Dec 1, 2003
last updated
Apr 6, 2025
detailed description
Single centre, open-label, randomised, three-way crossover study in 12 healthy volunteers. The study consisted of three 8-day treatment periods separated by washout periods of 10-15 days. On each of the treatment periods the volunteers received either a daily oral dose of BIA 2-093 900 mg once-daily (od), BIA 2-093 450 mg twice-daily (bid), or Oxcarbazepine (Trileptal®) 450 mg bid.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol